Myomo (MYO) Stock

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has priced an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $5.00 per share. Myomo expects the gross proceeds from this offering to be approximately $15.0 million, before deducting the underwriting discount.

Myomo, Inc. (MYO) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.06 per share a year ago.

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the official launch of the Myomo Academy, a comprehensive learning management system for professionals in Orthotics & Prosthetics (O&P) and Rehabilitation. The Myomo Academy is being launched during the 2024 AOPA (American Orthotic and Prosthe.

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, chairman and chief executive officer and David Henry, chief financial officer, will present and host one-on-one meetings with investors at the Sidoti Virtual Investor conference being held on June 12-13, 2024. Management's presentat.

Myomo, Inc. will release its financial results for the first quarter of 2024 on May 8, 2024, and will hold a conference call at 4:30 p.m. ET that same day with remarks by chairman and chief executive Paul R. Gudonis.

Medicare decision created a multi-decade revenue growth opportunity. Soft Q1 guidance due to non-recurring timing issues. 2024 guidance gives only partial-year credit to reimbursement change.

Myomo, Inc. (MYO) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.29 per share a year ago.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Myomo, Inc. (MYO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Market undervalues MYO stock due to poor understanding of CMS process. MYO is able to generate revenues in excess of $100mm/yr. MYO valuation gap will close before February 2024, when the final CMS price is published.